middle.news
AFT Pharmaceuticals Eyes $300M Revenue as FDA Clears Injectable Iron Phase III Trial
7:31am on Wednesday 24th of June, 2026 AEST
•
Pharmaceuticals
Read Story
AFT Pharmaceuticals Eyes $300M Revenue as FDA Clears Injectable Iron Phase III Trial
7:31am on Wednesday 24th of June, 2026 AEST
Key Points
FY26 revenue up 22% to NZ$254.7 million
Operating profit hits NZ$24.4 million, exceeding guidance
FDA approves Phase III trial for injectable iron project
Global sales reach 87 countries with strong international growth
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Aft Pharmaceuticals (ASX:AFP)
OPEN ARTICLE